The Journal of Clinical Investigation (Aug 2022)

Disrupting the DREAM complex enables proliferation of adult human pancreatic β cells

  • Peng Wang,
  • Esra Karakose,
  • Carmen Argmann,
  • Huan Wang,
  • Metodi Balev,
  • Rachel I. Brody,
  • Hembly G. Rivas,
  • Xinyue Liu,
  • Olivia Wood,
  • Hongtao Liu,
  • Lauryn Choleva,
  • Dan Hasson,
  • Emily Bernstein,
  • Joao A. Paulo,
  • Donald K. Scott,
  • Luca Lambertini,
  • James A. DeCaprio,
  • Andrew F. Stewart

Journal volume & issue
Vol. 132, no. 15

Abstract

Read online

Resistance to regeneration of insulin-producing pancreatic β cells is a fundamental challenge for type 1 and type 2 diabetes. Recently, small molecule inhibitors of the kinase DYRK1A have proven effective in inducing adult human β cells to proliferate, but their detailed mechanism of action is incompletely understood. We interrogated our human insulinoma and β cell transcriptomic databases seeking to understand why β cells in insulinomas proliferate, while normal β cells do not. This search reveals the DREAM complex as a central regulator of quiescence in human β cells. The DREAM complex consists of a module of transcriptionally repressive proteins that assemble in response to DYRK1A kinase activity, thereby inducing and maintaining cellular quiescence. In the absence of DYRK1A, DREAM subunits reassemble into the pro-proliferative MMB complex. Here, we demonstrate that small molecule DYRK1A inhibitors induce human β cells to replicate by converting the repressive DREAM complex to its pro-proliferative MMB conformation.

Keywords